clinical trial · NCT07583771
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
Chipscreen Biosciences, Ltd.·phase1·not yet recruiting·n = 186
Pancreatic AdenocarcinomaNon Small Cell Lung CancerAdvanced Solid TumorsLymphomaDiffuse Large B-Cell Lymphoma (DLBCL)CS08399
brief summary
This is a phase I, open-label, first-in-human study of CS08399, comprising two phases: dose escalation (including single-dose and multiple-dose) and cohort expansion. The primary objectives of this study are to evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of CS08399 in participants with MTAP-deleted solid tumors and Lymphoma, and to recommended Phase 2 dose(s) (RP2D) of CS08399 in appropriate tumor(s).
started
Jun 1, 2026
primary completion
Aug 1, 2029
completion
Jan 1, 2030
last updated
May 13, 2026
official title
A Phase Ⅰ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic and Preliminary Efficacy of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol